Literature DB >> 23893863

High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum.

Justin L Poklis1, Jezelle Charles, Carl E Wolf, Alphonse Poklis.   

Abstract

2CC-NBOMe {4-chloro-2,5-dimethoxyphenethyl-N-[(2-methoxyphenyl) methyl] ethanamine} and 25I-NBOMe {2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl] ethanamine} are of a class of N-benzyl phenethylamine derivatives whose synthesis was first reported in the scientific literature in 2011. Recent reports from 'personal drug experience websites' and in the popular press indicate these drugs are the latest in a series of designer 'Bath Salt' drugs of abuse. The presented high-performance liquid chromatography triple quadrupole mass spectrometry (HPLC/MS/MS) method was developed for the detection and quantification of 2CC-NBOMe and 25I-NBOMe in serum of intoxicated emergency department patients. The assay applies 2-​(2,​5-​dimethoxyphenyl)-​N-​(2-​methoxybenzyl) ethanamine (25H-NBOMe) as the internal standard. Samples were extracted using solid-phase extraction columns. The chromatographic separation was performed on a Luna 3 µ C8(2) 100 Å, 100 × 2.0 mm, column. Detection was accomplished by multiple-reaction monitoring via an electrospray ionization source operating in the positive ionization mode. The calibration curves were linear over the investigated concentration range, 30-2000 pg/mL, with a lower limit of detection of 10 pg/mL for both 2CC-NBOMe and 25I-NBOMe. The method proved suitable for serum clinical toxicology testing. Two severely intoxicated emergency department patients were determined to have serum concentrations of 250 and 2780 pg/mL of 25I-NBOMe using the presented method.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  25I-NBOMe; 2CC-NBOMe; Desinger Drugs; HPLC/MS/MS

Mesh:

Substances:

Year:  2013        PMID: 23893863      PMCID: PMC4077323          DOI: 10.1002/bmc.2999

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

1.  Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

Authors:  Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
Journal:  Mol Pharmacol       Date:  2006-09-25       Impact factor: 4.436

2.  High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.

Authors:  David E Nichols; Stewart P Frescas; Benjamin R Chemel; Kenneth S Rehder; Desong Zhong; Anita H Lewin
Journal:  Bioorg Med Chem       Date:  2008-04-25       Impact factor: 3.641

Review 3.  'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist.

Authors:  Simon Gibbons
Journal:  Clin Toxicol (Phila)       Date:  2012-01       Impact factor: 4.467

4.  Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers.

Authors:  Anders Ettrup; Martin Hansen; Martin A Santini; James Paine; Nic Gillings; Mikael Palner; Szabolcs Lehel; Matthias M Herth; Jacob Madsen; Jesper Kristensen; Mikael Begtrup; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

5.  A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug.

Authors:  S Rutherfoord Rose; Justin L Poklis; Alphonse Poklis
Journal:  Clin Toxicol (Phila)       Date:  2013-03       Impact factor: 4.467

6.  25C-NBOMe--new potent hallucinogenic substance identified on the drug market.

Authors:  Dariusz Zuba; Karolina Sekuła; Agnieszka Buczek
Journal:  Forensic Sci Int       Date:  2012-09-16       Impact factor: 2.395

7.  Identification and characterization of 2,5-dimethoxy-3,4-dimethyl-β-phenethylamine (2C-G)--a new designer drug.

Authors:  Dariusz Zuba; Karolina Sekuła
Journal:  Drug Test Anal       Date:  2012-08-23       Impact factor: 3.345

  7 in total
  7 in total

1.  "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion.

Authors:  Joji Suzuki; Justin L Poklis; Alphonse Poklis
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

Review 2.  Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature.

Authors:  Joji Suzuki; Michael A Dekker; Erin S Valenti; Fabiola A Arbelo Cruz; Ady M Correa; Justin L Poklis; Alphonse Poklis
Journal:  Psychosomatics       Date:  2014-11-06       Impact factor: 2.386

3.  Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.

Authors:  Justin L Poklis; Sara K Dempsey; Kai Liu; Joseph K Ritter; Carl Wolf; Shijun Zhang; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2015-10       Impact factor: 3.367

4.  Evolution of the NBOMes: 25C- and 25B- Sold as 25I-NBOMe.

Authors:  Larissa K Laskowski; Faesal Elbakoush; Jessica Calvo; Gina Exantus-Bernard; Jane Fong; Justin L Poklis; Alphonse Poklis; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2015-06

5.  Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death.

Authors:  Justin L Poklis; Kelly G Devers; Elise F Arbefeville; Julia M Pearson; Eric Houston; Alphonse Poklis
Journal:  Forensic Sci Int       Date:  2013-10-18       Impact factor: 2.395

6.  High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens.

Authors:  Justin L Poklis; Deborah J Clay; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-02-16       Impact factor: 3.367

Review 7.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.